Cannabidiol Modulates Glutamate and Learning in Psychosis
A single dose of cannabidiol glutamate psychosis modulation reduced abnormal brain activity in people at clinical high risk for psychosis. CBD may normalize glutamate-related neurotransmission patterns contributing to psychosis risk. This supports…
Cannabidiol Clinical Trials: High Risk Psychosis Research
Cannabidiol clinical trials reveal how a single dose of CBD affects hippocampal glutamate and brain activation in high risk psychosis. These trials suggest CBD's potential to normalize brain chemistry in early psychosis. Ongoing research aims to confirm…
Clinical Research on CBD’s Impact on Hippocampal Glutamate in Psychosis
CBD hippocampal glutamate modulation psychosis research reveals how a single dose of CBD affects brain activity during memory tasks. This modulation may normalize disrupted glutamate signaling in early psychosis. These findings highlight CBD’s potential…
Cannabidiol Clinical Trials: CBD, Psychosis Risk & Brain
Cannabidiol clinical trials high risk psychosis research show that a single dose of CBD influences hippocampal glutamate levels and prefrontal brain activation. This modulation may affect memory processing pathways disrupted in early psychosis. These…
Cannabinoid Clinical Trials: CBD, Psychosis & Brain Function
This study investigates CBD hippocampal glutamate modulation in individuals at clinical high risk for psychosis. Findings reveal CBD influences brain activity during verbal memory tasks. These results highlight CBD's potential neurochemical effects…